Immorta Bio Says a First Patient Has Received Its Senolytic Peptide, SenoMune-0257

What the company says happened

In a release dated November 2, Immorta Bio says the first patient was treated on October 29 at a private cancer centre in Mexico. It describes the setting as an independently conducted, investigator-initiated study: Immorta made and supplied the peptide, and outside investigators run the study and look after the patient. The release does not say how many patients the study will enrol, what dose was given, how it was given, or what the study measures. It says that safety and efficacy in humans have not been established.

What SenoMune-0257 is

Senescent cells are cells that have stopped dividing but do not die. They build up with age and release inflammatory signals, and drugs that remove them are called senolytics. Most senolytics tested so far are small-molecule drugs. Immorta's approach is different: it aims to teach the immune system to attack these cells, like a vaccine.

According to the company, SenoMune-0257 is a nine-amino-acid peptide picked out with AI-assisted methods, and the successor to its earlier product, SenoVax. The release does not give the peptide's sequence or which protein it comes from. SenoVax was a cell therapy: immune cells called dendritic cells loaded with material from senescent cells. Its published results, two papers by company scientists in the Journal of Translational Medicine, come from mice, in tumour, liver-injury and accelerated-ageing models. Neither paper tests SenoMune-0257.

Is there a registered trial?

We found none. On November 4 we searched ClinicalTrials.gov, the ISRCTN registry and the EU clinical trials register for SenoMune, SenoVax and Immorta Bio, and the release itself names no registration number. We could not search Mexico's national registry, so we cannot rule out a record there. Registration matters because it fixes in public, before results come in, what a study will measure and how many people it will treat.

What is not known

• Whether the patient had any benefit or side effects. No result has been reported.
• The dose, the route and the treatment schedule.
• The peptide's sequence and target, and any animal data on the peptide itself.
• How many patients will be treated, and when results will be shared.

The release's quotes come from the company's own leaders and from an oncologist who sits on its advisory board and co-wrote both SenoVax papers. The claim to be the first such treatment in a human is the company's own, and we could not check it.

What it means for readers

This is one dose in one patient, announced by the company that makes the product. It is not evidence that SenoMune-0257 works or is safe. The peptide is not sold anywhere and is not approved anywhere; anything offered online under this name would not be the company's product.

Related on Grey Peptides